Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model

British Journal of Cancer

Volumn 84, Issue 6, 2001, Pages 859-863

  Miyake, H ^a   Hara, S ^a   Arakawa, S ^a   Kamidono, S ^a   Hara, I ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Androgen independent progression; Apoptosis; Castration; Mitoxantrone; Prostate cancer

Indexed keywords

ANDROGEN; MITOXANTRONE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; MALE; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOXANTRONE; MODELS, BIOLOGICAL; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 0035937336     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1686     Document Type: Article

References (12)

1. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
2. Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European Organization for Research in Cancer Therapy Genitourinary Group trial
3. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model
4. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer
5. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
6. Comparison of hormonal therapy and chemohormonal therapy in patients with newly diagnosed clinical stage D prostate cancer
7. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer
8. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2, in prostate cancer xenograft models
9. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
10. Management of hormone refractory prostate cancer: Current standards and future prospects
11. Target to apoptosis: A hopeful weapon for prostate cancer
12. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points